Umberto Pensato։ Left Ventricular Dysfunction and DOAC Benefit in ESUS
Umberto Pensato, Assistant Professor of Neurology at the Humanitas University, Research Collaborator at the University of Calgary, shared on X about a recent article by Richa Sharma et al., published in Stroke, adding:
”Super important ARCADIA post hoc!
LV dysfunction is a treatment effect modifier of DOACs for stroke prevention.
(ie DOAC benefits only in ESUS with LV dysfunction).”
Title: Apixaban and Recurrent Stroke Risk With Left Ventricular Dysfunction: A Secondary Analysis of the ARCADIA Trial
Authors: Richa Sharma, Dinesh Jillella, Cenai Zhang, Mitchell S.V. Elkind, Hooman Kamel, Marco R. Di Tullio, Richard A. Kronmal, Balaji Krishnaiah, Shadi Yaghi, W.T. Longstreth Jr, David L. Tirschwell, Alexander E. Merkler, Fadi Nahab
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 30, 2026, 05:18Flora Peyvandi: Molecular and Lab Markers Linked to Bleeding Severity in Factor VII Deficiency
-
Oct 30, 2026, 05:11Rana Al-Hrout: Exploring Approach to Macrocytic Anemia
-
Oct 30, 2026, 04:22Francisco Chacón-Lozsán: Acute Pulmonary Embolism in 2026 – Blood Pressure Is Not the Same as Perfusion
-
Oct 30, 2026, 04:15Samin Mohsenian: Launching the PRO-RBDD-FX Registry for Rare Coagulation Factor X Deficiency
-
Oct 30, 2026, 03:59Emil List Larsen: Identifying SERPINC1 Variants and Limitations of Routine Antithrombin Testing
-
Oct 30, 2026, 02:43D Chandra: Reduce the Apixaban Dose for a Patient with VTE and a Creatinine Clearance of 25?
-
Oct 30, 2026, 02:38Spencer Dorn: Why AI Decision Support Must Integrate Local Clinical Context
-
Oct 30, 2026, 02:33Jens Eschen: Randomized Controlled Trial on Acute Aortic Dissection Anticoagulation Strategies
-
Oct 30, 2026, 02:23Mavis Agnes Kisakye: Landmark Study Paves the Way for Standardized Bleeding Disorder Guidelines in Uganda